Pulmonary Medicine · COPD · Article / Review
COPD is not just airflow obstruction
Lede: COPD is a heterogeneous physiologic syndrome in which airflow obstruction is only one part of the disease.
Why it matters
Two people with the same FEV₁ can have very different breathlessness, exercise capacity, gas trapping, gas exchange, exacerbation risk, and treatment needs. Spirometry establishes airflow obstruction, but it does not fully describe the physiology that makes a patient symptomatic. A useful COPD assessment therefore asks not only how obstructed are the airways?, but also what is limiting this particular patient?
1. FEV₁ tells you how fast air leaves — not the whole story
Post-bronchodilator airflow obstruction remains central to diagnosing COPD, and FEV₁ is useful for grading the severity of airflow limitation. But FEV₁ alone cannot tell you how much the lungs are hyperinflated, whether diffusion is impaired, why the patient becomes dyspneic during exertion, or how often the disease destabilizes.
That is why modern COPD assessment separates the physiologic measurement of airflow obstruction from the clinical dimensions that determine burden: symptoms, prior exacerbations, exercise limitation, comorbid disease, and treatment response.
2. Hyperinflation can be the hidden engine of dyspnea
Expiratory flow limitation can prevent the lungs from emptying before the next breath begins. End-expiratory lung volume rises, inspiratory capacity falls, and the next tidal breath must begin at a higher operating lung volume.
During exercise, this can become dynamic hyperinflation. As respiratory rate rises, expiratory time shortens and the patient may progressively trap more gas. The inspiratory muscles are forced to work near total lung capacity, where further tidal expansion becomes mechanically constrained. The result is the familiar clinical complaint: “I can breathe in, but I cannot get enough air out.”
This is one reason a patient with only moderate reduction in FEV₁ may still have severe exertional dyspnea.
3. DLCO asks a different physiologic question
A reduced diffusing capacity can reflect loss of alveolar-capillary surface area from emphysema, pulmonary vascular disease, anemia, or a mixed pulmonary process. In COPD, a low DLCO should therefore not be treated as merely another measure of obstruction.
When dyspnea appears disproportionate to spirometry, DLCO, lung volumes, exercise oximetry, echocardiographic information, or cardiopulmonary exercise testing may uncover physiology that FEV₁ cannot.
4. Exacerbations are a phenotype of their own
A patient with relatively preserved day-to-day function may still have recurrent exacerbations, while another patient with severe chronic symptoms may rarely exacerbate. These patterns matter because exacerbation history is one of the strongest practical predictors of future events and directly influences preventive treatment.
Exacerbations are also heterogeneous. Infection, airway inflammation, environmental exposure, cardiac disease, pulmonary embolism, and other processes can produce overlapping presentations. The label “COPD exacerbation” should therefore start — not end — the clinical reasoning.
5. Treat the dominant problem, not just the spirometry grade
The practical value of phenotyping COPD is that different mechanisms invite different interventions. Bronchodilation can reduce airflow limitation and hyperinflation. Pulmonary rehabilitation addresses deconditioning, skeletal-muscle dysfunction, and exertional intolerance. Inhaled corticosteroids are most useful in selected patients with an exacerbation-prone, eosinophilic pattern rather than as universal therapy. Smoking cessation, vaccination, oxygen when appropriately indicated, treatment of sleep-disordered breathing, and management of cardiovascular and metabolic comorbidities may be equally important.
The objective is not to accumulate medications. It is to identify the physiologic and clinical drivers of the patient’s limitation and target them deliberately.
The takeaway
Treat the patient’s COPD physiology and phenotype — not the FEV₁ in isolation. Airflow obstruction establishes an important part of the diagnosis, but hyperinflation, gas exchange, exacerbation biology, exercise limitation, and comorbid disease often explain what the patient actually experiences.
Go deeper
- GOLD 2026 Report — Global Strategy for the Diagnosis, Management, and Prevention of COPD
- O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med. 2001.
- O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in COPD. Proc Am Thorac Soc. 2006.
Educational content for clinicians and trainees. This material does not replace individualized clinical judgment or patient-specific medical care.
